{
    "data": [
        {
            "id": "69a03bdc24c37e0001bb40ad",
            "title": "Nexstar Media Gr: Q4 Earnings Insights",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Nexstar Media Gr</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NXST\" target=\"_blank\">NXST</a>) just disclosed its Q4 earnings on Thursday, February 26, 2026 at 07:00 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a brief overview of the earnings report.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Nexstar Media Gr beat estimated earnings by 85.79%, reporting an EPS of $6.93 versus an estimate of $3.73.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was down $199.00 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Analysis of Past Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">During the previous quarter, the company missed on EPS by $0.01, leading to a 0.71% increase share price change the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Nexstar Media Gr's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Nexstar Media Gr <a href=\"https://www.benzinga.com/quote/NXST/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_3.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50883304/nexstar-media-gr-q4-earnings-insights",
            "pub_date": "2026-02-26 20:26:08",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a03be224c37e0001bb40b5",
            "title": "Earnings Summary: Entrada Therapeutics Q4",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\">The earnings results for <strong>Entrada Therapeutics</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/TRDA\" target=\"_blank\">TRDA</a>) for Q4 were made public on Thursday, February 26, 2026 at 07:00 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a comprehensive overview of the announcement.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Entrada Therapeutics beat estimated earnings by 22.95%, reporting an EPS of $-0.94 versus an estimate of $-1.22.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was down $36.10 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Historical Earnings Summary</h3><!--/$--><!--$--><p class=\"block core-block\">Last quarter the company missed on EPS by $0.07 which was followed by a 0.58% drop in the share price the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Entrada Therapeutics's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\"><strong> Listen to the earnings announcement yourself by <a href=\"\" target=\"_blank\">clicking here</a>. </strong></p><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Entrada Therapeutics <a href=\"https://www.benzinga.com/quote/TRDA/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_2.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50883313/earnings-summary-entrada-therapeutics-q4",
            "pub_date": "2026-02-26 20:26:13",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0398324c37e0001bb3f95",
            "title": "Nuveen Churchill Direct: Q4 Earnings Insights",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Nuveen Churchill Direct</strong> (NYSE:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/NCDL\" target=\"_blank\">NCDL</a>) just disclosed its Q4 earnings on Thursday, February 26, 2026 at 07:15 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a brief overview of the earnings report.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Nuveen Churchill Direct beat estimated earnings by 2.33%, reporting an EPS of $0.44 versus an estimate of $0.43.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was down $7.04 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Analysis of Past Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Last quarter the company missed on EPS by $0.03 which was followed by a 0.91% drop in the share price the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Nuveen Churchill Direct's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Nuveen Churchill Direct <a href=\"https://www.benzinga.com/quote/NCDL/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_7.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50883027/nuveen-churchill-direct-q4-earnings-insights",
            "pub_date": "2026-02-26 20:16:07",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a039fb24c37e0001bb3fe9",
            "title": "ACM Research Q4 Earnings Report: What Investors Need to Know",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>ACM Research</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ACMR\" target=\"_blank\">ACMR</a>) reported its Q4 earnings results on Thursday, February 26, 2026 at 07:00 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's what investors need to know about the announcement.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">ACM Research missed estimated earnings by -26.47%, reporting an EPS of $0.25 versus an estimate of $0.34.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was up $20.96 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Performance in Previous Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">During the previous quarter, the company missed on EPS by $0.09, leading to a 0.71% drop share price change the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at ACM Research's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for ACM Research <a href=\"https://www.benzinga.com/quote/ACMR/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_8.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50883109/acm-research-q4-earnings-report-what-investors-need-to-know",
            "pub_date": "2026-02-26 20:18:07",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        },
        {
            "id": "69a0390b24c37e0001bb3f29",
            "title": "Aclaris Therapeutics Q4 Earnings Summary &amp; Key Takeaways",
            "description": "<div><div class=\"sc-gfrmXj kPLDLR\"><!--$--><p class=\"block core-block\"><strong>Aclaris Therapeutics</strong> (NASDAQ:<a class=\"ticker\" href=\"https://www.benzinga.com/quote/ACRS\" target=\"_blank\">ACRS</a>) reported its Q4 earnings results on Thursday, February 26, 2026 at 06:58 AM.</p><!--/$--><!--$--><p class=\"block core-block\">Here's what investors need to know about the announcement.</p><!--/$--><!--$--><h3 class=\"block core-block\">Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">Aclaris Therapeutics missed estimated earnings by -14.29%, reporting an EPS of $-0.16 versus an estimate of $-0.14.</p><!--/$--><!--$--><p class=\"block core-block\">Revenue was down $7.92 million from the same period last year.</p><!--/$--><!--$--><h3 class=\"block core-block\">Analysis of Past Earnings</h3><!--/$--><!--$--><p class=\"block core-block\">During the previous quarter, the company beat on EPS by $0.02, leading to a 2.2% increase share price change the next day.</p><!--/$--><!--$--><p class=\"block core-block\">Here's a look at Aclaris Therapeutics's past performance:</p><!--/$--><!--$?--><template id=\"B:2\"></template><div></div><!--/$--><!--$--><p class=\"block core-block\">To track all earnings releases for Aclaris Therapeutics <a href=\"https://www.benzinga.com/quote/ACRS/earnings\" target=\"_blank\">visit their earnings calendar here.</a> </p><!--/$--><!--$--><p class=\"block core-block\">This article was generated by Benzinga's automated content engine and reviewed by an editor.</p><!--/$--></div></div>",
            "image": "https://www.benzinga.com/files/images/story/2025/11/06/analyst_ratings_6.jpg",
            "link": "https://www.benzinga.com/insights/earnings/26/02/50882925/aclaris-therapeutics-q4-earnings-summary-key-takeaways",
            "pub_date": "2026-02-26 20:14:06",
            "source": "benzinga",
            "kind": 1,
            "language": "en"
        }
    ]
}